Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.

UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut (2015) 1.20

Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94

Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol (2015) 0.86

Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76

To block, or not to block in advanced cirrhosis and ascites: that is the question. Gut (2014) 0.76

Use of Non-selective Beta-blockers in Decompensated Cirrhosis: Controversy Continues. J Clin Exp Hepatol (2015) 0.75

Continued controversy over the safety of beta-blockers in decompensated cirrhosis. Hepatology (2015) 0.75

Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol (2016) 0.75

A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol (2016) 0.75

Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol (2015) 0.75

Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol (2016) 0.75

Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis. Gut Liver (2016) 0.75

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75

Chronic kidney disease after liver transplantation. J Hepatol (2014) 1.06

Beta-blockers in portal hypertension: new developments and controversies. Liver Int (2013) 0.84

The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. J Hepatol (2014) 0.79

Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int (2016) 0.75